Philippe Parone
Chief Scientific Officer Esobiotec
Dr. Philippe Parone is a scientific innovator and biotechnology leader with over 25 years of experience spanning academia and industry. He earned a Ph.D. in Biochemistry from the University of Cambridge and trained at the University of Geneva and UC San Diego. At Fate Therapeutics, he led iPSC-derived immunoregulatory cell therapy programs for immune disorders and contributed to the first IND approval for an engineered iPSC-derived NK cell therapy. As Director of Industrialization at Celyad Oncology, he advanced CAR-T therapies to first-in-human trials. As Chief Scientific Officer at EsoBiotec, he leads next-generation in vivo cell therapy programs, achieving the first worldwide clinical validation of a CAR-T in vivo therapy.
Seminars
- Rotate through the tables to learn from Pharma and C-level executives with partnership experience, and gain practical insights to shape your future strategy
- Key preclinical data supporting the engineered features of the ENaBL vector for T-cell reprogramming
- Present clinical data demonstrating the safety and efficiency of ENaBL’s in-vivo BCMA CAR-T reprogramming in patients with multiple myeloma
- Highlight key clinical outcomes on response rates, persistence, and safety profile compared to ex-vivo approaches
- Share how biotechs can present data and strategy in ways that help investors and pharma make faster, more confident decisions, reducing risk on both sides
- Highlight how pharma and investors can communicate expectations more clearly ensuring companies design studies and pipelines that are partner-ready
